BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Golden Meditech Acquires Convertible Notes to Increase Stake in Hospital Management Business


8/27/2012 10:49:26 AM

HONG KONG, Aug. 24, 2012 /PRNewswire-Asia/ -- Golden Meditech Holdings Limited ("Golden Meditech" , together with its subsidiaries collectively as the "Group" , - 801.HK; 910801.TW), a leading integrated healthcare enterprise in China, is increasing its ownership in hospital management business by acquiring the US$28,000,000 principal value Senior 5% Redeemable Convertible Notes due 2014 ("Convertible Notes") issued by its non-wholly-owned hospital management subsidiary, GM Hospital Group Limited ("GMHG") from its strategic investor, New Horizon Capital III, L.P. ("New Horizon"). In return, New Horizon will receive 279,344,444 new shares at the issue price of HK$0.9 per share ("Consideration Shares"), representing approximately 12.31% of the enlarged issued share capital. Assuming Golden Meditech elects to convert all the Convertible Notes into new GMHG shares, Golden Meditech's shareholding in GMHG will increase to approximately 78.58%. Pursuant to the agreement, New Horizon has undertaken not to dispose the Consideration Shares in any form within the period of 3 months from the completion of the agreement.

"Economic growth has improved living standards in China and a consequent outcome of this has been the growth of the premium healthcare services sector. With the launch of favourable policies from the government for the healthcare services industry, we believe the future prospects of China's hospital management market will be robust," said Mr. Kam Yuen, Chairman and Chief Executive Officer of Golden Meditech. "We are glad of the opportunity to increase our stake in the hospital management subsidiary in order to accomplish our vision in this business as well as support our new hospital facility in Beijing which is expected to be operational by the end of this year. Concurrently, bringing in New Horizon as a strategic investor has affirmed the support of investors on our strategy. Golden Meditech is committed to building itself into a comprehensive healthcare enterprise driven by both medical devices and healthcare services businesses to create the greatest value for our shareholders."

About Golden Meditech Holdings Limited

Golden Meditech Holdings Limited is China's leading integrated-healthcare enterprise. Golden Meditech is a first-mover in China, having established dominant positions in medical devices and healthcare services markets, thanks to its strengths in innovation and market expertise and the ability to capture emerging market opportunities. Going forward, the Group will continue to pursue a leading position in China's healthcare industry both through organic growth and strategic expansion.

SOURCE Golden Meditech Holdings Limited



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES